IBB Fact Sheet

iShares Biotechnology ETF

$199.54
close, Nov 20, 2026

Over the year to Nov 19, 2026, IBB returned +23.6% in total and charged 0.44% a year.

1-year total return	Expense ratio	Net assets	Net flow, last 5 trading days
+21.7% to Nov 20, 2026	**0.44%** a year	**$10.8bn** on Nov 19, 2026	**+$165m** daily basis to Nov 19, 2026

Growth of $10,000, 1 year



IBB **$12,355** +23.6% · PBUS **$10,892** +8.9% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WINDOW	TOTAL RETURN
1 month	**-5.7%**
3 months	**-6.6%**
Year to date	**+18.3%**
1 year	**+21.7%**
3 years	**+70.4%**
5 years	**+30.7%**

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HOLDING	WEIGHT
GILEAD SCIENCES	**9.32%**
AMGEN INC	**8.36%**
VERTEX PHARMACEUTICALS	**7.83%**
REGENERON PHARMACEUTICALS	**6.63%**
MODERNA	**5.28%**
ARGENX SE ADR	**3.79%**
NATERA	**2.83%**
BIOGEN	**2.63%**
BEONE MEDICINES AG	**2.44%**
INSMED	**2.25%**

IBB top ten by weight, 51.4% of the fund, of its 245 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Holds 245 stocks in biotech, 43% of its weight in S&P 500 companies · First traded Feb 12, 2001 · Benchmark Its own holdings, as of Nov 19, 2026

ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/ibb.